Regeneron, Sanofi Report Positive Libtayo Results in Advanced Basal Cell Carcinoma
May 05 2020 - 10:57AM
Dow Jones News
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Tuesday said
Libtayo showed clinically meaningful and durable responses in
second-line advanced basal cell carcinoma in an open-label phase 2
study.
The companies said the study involves patients who had
progressed on or were intolerant to prior hedgehog pathway
inhibitor therapy, for whom there are currently no approved
treatments.
Regeneron and Sanofi said they plan to make regulatory filings
this year.
Basal cell carcinoma, a skin cancer, is the most common cancer
worldwide.
Sanofi and Regeneron last week said they had stopped a pivotal
phase 3 trial of Libtayo in advanced non-small cell lung cancer
early due to a highly significant improvement in positive overall
survival.
Regeneron, of Tarrytown, N.Y., and France's Sanofi are jointly
developing and commercializing Libtayo under a global collaboration
agreement.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 05, 2020 10:42 ET (14:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024
